Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolynovoCALZF -2.14%74 Debt-to-EBITDA is 2.43 as of Dec. 2025. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.20 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Polynovo ranks worse than 65.74% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Polynovo's Debt-to-EBITDA or its related term are showing as below:
CALZF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.92 Med: -0.65 Max: 14.6
Current: 2.65
During the past 13 years, the highest Debt-to-EBITDA Ratio of Polynovo was 14.60. The lowest was -5.92. And the median was -0.65.
CALZF's Debt-to-EBITDA is ranked worse than 65.74% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs CALZF: 2.65
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Polynovo Debt-to-EBITDA Related Terms
Polynovo Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Polynovo's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Polynovo's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Polynovo (CALZF) has a Debt-to-EBITDA of 2.43 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Polynovo. According to the industry distribution chart, Polynovo ranks #307 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 65.7%.
Is Polynovo's Debt-to-EBITDA too high?
Polynovo's current Debt-to-EBITDA is 2.43. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Polynovo's value of 2.43 is 54.8% above this industry median. Based on the distribution chart, Polynovo ranks #307 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #307 out of 467 companies for Debt-to-EBITDA. This places Polynovo in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Polynovo's value of 2.43 is 54.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current Debt-to-EBITDA of 2.43 is 54.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Polynovo. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current Debt-to-EBITDA is 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.20, compared to a current price of $0.59 — trading 73.2% below its estimated fair value. The current Debt-to-EBITDA is 2.43 and 54.8% above the Medical Devices & Instruments industry median of 1.57. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Polynovo (CALZF), the current Debt-to-EBITDA is 2.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.59 is trading 73.2% below its estimated GF Value™ of $2.20.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
Debt-to-EBITDA: 2.43
GF Value™: $2.20 vs. price of $0.59 (73.2% below fair value)
Industry Position: 54.8% above the Medical Devices & Instruments median (#307 of 467)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
